Volltext verfügbar nach Anmeldung bzw. im Campus-Netz.
Specific KIR-HLA genotypes predict outcomes in refractory or relapsed primary central nervous system lymphoma.
In: Hematology, Jg. 28 (2023-12-01), Heft 1, S. 1-8
Online
academicJournal
Zugriff:
An effective salvage regimen for the reinduction of remission is lacking for refractory or relapsed primary central nervous system lymphoma (r/r PCNSL). This study aimed to evaluate the efficacy and safety of cytarabine plus temozolomide in treating r/r PCNSL and to explore the associated prognostic factors. A single-center retrospective cohort study was conducted to assess the efficacy and safety of cytarabine and temozolomide (AT) in r/r PCNSL patients. KIR and HLA genotyping was performed on peripheral blood samples. Thirty PCNSL patients receiving an AT regimen (cytarabine 3 g/m2 for 2 days combined with temozolomide 150 mg/m2 for 5 days) in our institution were analyzed. The median age was 65 years (range 25–79 years). A total of 43.4% of patients (13/30) achieved an overall response within a median follow-up of 16 months (95% confidence interval [CI]: 11–23 months). The median PFS and OS of the cohort were 1.5 months (95% CI: 1–4 months) and 19.5 months (95% CI: 11 months to not calculable), respectively. Patients harboring KIR3DL1/HLA-B genotypes predicting low affinity had a higher response rate (p = 0.042) and longer median PFS (3 months) than those with KIR3DL1/HLA-B genotypes predicting high affinity (1 month) (p = 0.0047). Cox regression analysis indicated that KIR/HLA-B genotypes were independently associated with PFS (p = 0.043). However, KIR/HLA-B genotypes had no impact on the OS of the cohort. The toxicity of AT treatment was mild and manageable. The AT regimen was well tolerated, and patients with specific KIR-HLA genotypes may benefit from this regimen. [ABSTRACT FROM AUTHOR]
Titel: |
Specific KIR-HLA genotypes predict outcomes in refractory or relapsed primary central nervous system lymphoma.
|
---|---|
Autor/in / Beteiligte Person: | Lin, Zhiguang ; Xu, Huiwen ; Ma, Jingjing ; Ma, Yan ; Li, Qing ; Kang, Hui ; Zhang, Mengxue ; Chen, Bobin |
Link: | |
Zeitschrift: | Hematology, Jg. 28 (2023-12-01), Heft 1, S. 1-8 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 1024-5332 (print) |
DOI: | 10.1080/16078454.2023.2243424 |
Schlagwort: |
|
Sonstiges: |
|